<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00491803</url>
  </required_header>
  <id_info>
    <org_study_id>SIL-COPD-01</org_study_id>
    <secondary_id>EudraCT #: 2007-000116-81</secondary_id>
    <nct_id>NCT00491803</nct_id>
  </id_info>
  <brief_title>Sildenafil Effects on Pulmonary Haemodynamics and Gas Exchange in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <acronym>SIL-COPD-01</acronym>
  <official_title>Acute Effects of a Single Dose of Sildenafil (20mg/40mg) on Pulmonary Haemodynamics and Gas Exchange at Rest and During Exercise in COPD Patients With Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sildenafil is a phosphodiesterase-5 inhibitor that has been approved for the treatment of
      pulmonary arterial hypertension with orphan drug designation. Sildenafil modulates the nitric
      oxide (NO) pathway in the vessel wall. Since this pathway is impaired in pulmonary arteries
      of patients with pulmonary hypertension (PH) associated with chronic obstructive pulmonary
      disease (COPD), we hypothesized that sildenafil might improve pulmonary hemodynamics and
      increase exercise tolerance in this condition. However, in COPD sildenafil may also impair
      gas exchange due to the inhibition of pulmonary hypoxic vasoconstriction. The research
      project is aimed to evaluate these effects.

      It is a prospective, randomized, double-blind study to evaluate the acute effects of a single
      dose of 20 or 40 mg of sildenafil on gas exchange and pulmonary hemodynamics. Subjects: 20
      patients (10 in each group). Measurements: pulmonary hemodynamics, arterial blood gasses and
      ventilation-perfusion distributions; at rest and during sub-maximal exercise.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of mean PAP and PVR</measure>
    <time_frame>60 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CO, PaO2, V/Q</measure>
    <time_frame>60 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sildenafil 20mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sildenafil 40mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>sildenafil 20 mg orally</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>sildenafil 40 mg orally</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD (FEV1/FVC&lt;0.7)

          -  Age 40-75

          -  Pulmonary hypertension (Vmax TI&gt;=2.8m/sec)

        Exclusion Criteria:

          -  Treatment with CYP3A4 inhibitors, nitrates, PDE-5 inhibitors

          -  Coronary disease

          -  Ischemic optical neuritis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joan albert Barbera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2007</study_first_submitted>
  <study_first_submitted_qc>June 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2007</study_first_posted>
  <last_update_submitted>November 9, 2009</last_update_submitted>
  <last_update_submitted_qc>November 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>Joan Albert Barbera</name_title>
    <organization>Hospital Clinic Barcelona</organization>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

